Table 1 Biodistribution of 18F-mFBG 4 h after injection of mice bearing Kelly xenografts, pre-treated with AZD2014 (25 mg/kg/day) or vehicle control (DMSO 10%, PEG400 90%) for 3 days.

From: 18F-meta-fluorobenzylguanidine (18F-mFBG) to monitor changes in norepinephrine transporter expression in response to therapeutic intervention in neuroblastoma models

Kelly

18F-mFBG biodistribution 4 h p.i. (mean %ID/g ± SD)

Vehicle

AZD2014 (25 mg/kg/day)

N = 

3

3

Blood

0.22 ± 0.05

0.19 ± 0.03

Heart

6.34 ± 1.41

4.22 ± 0.85

Lungs

1.52 ± 0.22

1.31 ± 0.39

Kidney

1.11 ± 0.47

0.97 ± 0.17

Spleen

3.77 ± 0.82

4.58 ± 0.77

Liver

2.37 ± 0.71

2.08 ± 0.45

Pancreas

1.26 ± 0.28

1.25 ± 0.21

Tumour

0.39 ± 0.13

0.74 ± 0.25

Bone

1.43 ± 0.83

0.99 ± 0.07

Small intestine

6.57 ± 1.12

7.30 ± 1.11

Muscle

0.74 ± 0.23

0.64 ± 0.17

Brown adipose

5.84 ± 2.44

7.20 ± 0.88

Tumour:blood

1.75 ± 0.29

4.16 ± 1.89

Tumour:muscle

0.53 ± 0.01

1.23 ± 0.61

  1. Data are presented as mean ± SD, n = 3 per group.